stockrowOmeros Corporation
OMER Healthcare Biotechnology
- Revenue
- +35.5%
- EPS
- +141.9%
- Free cash flow
- +118.7%
- Total debt
- −42.0%
Quarter to June 2026, against a year earlier
Follow OMER
Alert me
Omeros Corporation (OMER) EV/Sales
As of 6 November 2026, Omeros Corporation (OMER) trades at a EV/Sales of 12.3×. Over the past ten years it has ranged from 0.8× (October 2023) to 1,660× (March 2015); the current reading is higher than 58% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 12.5× | 74.88% |
| FY2019 | 7.1× | (66.12%) |
| FY2018 | 21.1× | 48.94% |
| FY2017 | 14.2× | 33.07% |
| FY2016 | 10.6× | (76.53%) |
| FY2015 | 45.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.9× | (20.70%) |
| Mar 2026 | 8.7× | (30.57%) |
| Sep 2021 | 12.5× | (7.54%) |
| Jun 2021 | 13.5× | (26.93%) |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| GHRS GH Research PLC compare | n/m |
| LBRX LB Pharmaceuticals Inc compare | n/m |
| KARD KARDIGAN INC compare | n/m |
| MNKD MannKind Corporation compare | 3.8× |
| URGN Urogen Pharma compare | 5.4× |
| OMER Omeros Corporation | 12.3× |
| NKTR Nektar Therapeutics compare | 19.2× |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 1,025× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)